DTPA放射免疫显像预定位技术的建立及其临床应用  

Establishment of DTPA Pretargeted Scintigraphy Technique and It's Clinical Use

作　　者：庞雁[1] 牛瑞芳[1] 常克力[1] 何景华 张瑾[1] 邹永盛[1] 刘印忠 

机构地区：[1]天津市肿瘤医院,肿瘤研究所,天津医科大学

出　　处：《中国肿瘤临床》1996年第9期609-613,共5页Chinese Journal of Clinical Oncology

基　　金：天津市科委二十一世纪青年科学基金

摘　　要：为了使常规短半衰期放射性核素Ｉｎ－１１３Ｍ能够用于ＲＩＩ研究，作者对传统ＲＩＩ方法进行改进，建立了ＤＴＰＡ预定位技术，即首先将抗肿瘤抗体在体外偶联，注入体内，待３天后抗体与肿瘤结合，再注入游离Ｉｎ－１１３Ｍ。Ｉｎ－１１３Ｍ可与Ａｂ上的ＤＴＰＡ结合，从而可在注射Ｉｎ－１１３Ｍ后２小时达到肿瘤显像效果。ＤＴＰＡ预定位技术的建立，简化了ＲＩＩ的研究方法，有利于ＲＩＩ研究从科研阶段走向临床应用。In order to make use of rutinely short half-life radio-isotopes In113M in radioimmunoimaging(RII),we innovated the conventional method of RII and dveloped a DTPA pretargeted scintigraphy technique,in which tumor antibody (Ab)was conjugated with DTPA in vitro,and then injected to patient intravenously. Three days later,once the Ab had combined with tumor specifically,In-113M was injected into the body.In-113M could bind with DTPA quickly and scanning was performed in 2 hours.Twenty one cancer patients were studied using this tech nique,5 were negative and 16 positive.The concordance rate with the clinical diagnosis was 19 out of 21,and it was 10/10 with those Who had histoiogical diagnosis.It is suggested that DTPA pretargeted scintigraphy technique would make the RIIstudy simpler and be applied clinically.

关 键 词：DTPA 放射免疫显像 In-113M 肿瘤 诊断 

分 类 号：R730.44[医药卫生—肿瘤]